ADMA vs. ARQT

Last updated Apr 2, 2026

Compare and contrast key facts about ADMA Biologics, Inc. (ADMA) and Arcutis Biotherapeutics, Inc. (ARQT).

Performance

ADMA vs. ARQT - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in ADMA Biologics, Inc. (ADMA) and Arcutis Biotherapeutics, Inc. (ARQT). The values are adjusted to include any dividend payments, if applicable.

ADMA vs. ARQT - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020
ADMA ADMA Biologics, Inc.	-50.05%	6.36%	279.42%	16.49%	175.18%	-27.69%	-50.76%
ARQT Arcutis Biotherapeutics, Inc.	-17.01%	108.47%	331.27%	-78.18%	-28.64%	-26.27%	29.04%

Fundamentals

Market Cap ADMA : $2.22B ARQT : $3.27B
EPS ADMA : $0.60 ARQT : -$0.12
PS Ratio ADMA : 4.39 ARQT : 8.45
PB Ratio ADMA : 4.65 ARQT : 17.25
Total Revenue (TTM) ADMA : $510.17M ARQT : $376.07M
Gross Profit (TTM) ADMA : $292.77M ARQT : $339.38M
EBITDA (TTM) ADMA : $195.35M ARQT : -$1.11M

Returns By Period

In the year-to-date period, ADMA achieves a -50.05% return, which is significantly lower than ARQT's -17.01% return.

ADMA

• 1D: 1.11%
• 1M: -45.05%
• YTD: -50.05%
• 6M: -39.47%
• 1Y: -53.09%
• 3Y*: 40.14%
• 5Y*: 37.85%
• 10Y*: 0.79%

ARQT

• 1D: 2.29%
• 1M: -2.67%
• YTD: -17.01%
• 6M: 21.96%
• 1Y: 60.88%
• 3Y*: 29.88%
• 5Y*: -4.12%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

ADMA vs. ARQT — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ADMA

ADMA Risk / Return Rank: 7
ADMA Sharpe Ratio Rank: 5
ADMA Sortino Ratio Rank: 7
ADMA Omega Ratio Rank: 8
ADMA Calmar Ratio Rank: 11
ADMA Martin Ratio Rank: 3

ARQT

ARQT Risk / Return Rank: 72
ARQT Sharpe Ratio Rank: 74
ARQT Sortino Ratio Rank: 74
ARQT Omega Ratio Rank: 69
ARQT Calmar Ratio Rank: 72
ARQT Martin Ratio Rank: 72

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ADMA vs. ARQT - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for ADMA Biologics, Inc. (ADMA) and Arcutis Biotherapeutics, Inc. (ARQT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	ADMA	ARQT	Difference
Sharpe ratio Return per unit of total volatility	-0.93	1.02	-1.95
Sortino ratio Return per unit of downside risk	-1.32	1.85	-3.16
Omega ratio Gain probability vs. loss probability	0.83	1.22	-0.38
Calmar ratio Return relative to maximum drawdown	-0.82	1.69	-2.51
Martin ratio Return relative to average drawdown	-1.80	3.97	-5.76
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

ADMA vs. ARQT - Sharpe Ratio Comparison

The current ADMA Sharpe Ratio is -0.93, which is lower than the ARQT Sharpe Ratio of 1.02. The chart below compares the historical Sharpe Ratios of ADMA and ARQT, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	ADMA	ARQT	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.93	1.02	-1.95
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.63	-0.06	+0.69
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.01	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.01	0.02	-0.01

Correlation

The correlation between ADMA and ARQT is 0.27, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

ADMA vs. ARQT - Dividend Comparison

Neither ADMA nor ARQT has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

ADMA vs. ARQT - Drawdown Comparison

The maximum ADMA drawdown since its inception was -91.28%, roughly equal to the maximum ARQT drawdown of -95.02%. Use the drawdown chart below to compare losses from any high point for ADMA and ARQT.

Drawdown Indicators

	ADMA	ARQT	Difference
Max Drawdown Largest peak-to-trough decline	-91.28%	-95.02%	+3.74%
Max Drawdown (1Y) Largest decline over 1 year	-66.18%	-31.99%	-34.19%
Max Drawdown (5Y) Largest decline over 5 years	-66.18%	-94.71%	+28.53%
Max Drawdown (10Y) Largest decline over 10 years	-87.33%	—	—
Current Drawdown Current decline from peak	-62.83%	-34.83%	-28.00%
Average Drawdown Average peak-to-trough decline	-52.92%	-50.46%	-2.46%
Ulcer Index Depth and duration of drawdowns from previous peaks	30.12%	13.63%	+16.49%

Volatility

ADMA vs. ARQT - Volatility Comparison

ADMA Biologics, Inc. (ADMA) has a higher volatility of 32.15% compared to Arcutis Biotherapeutics, Inc. (ARQT) at 15.32%. This indicates that ADMA's price experiences larger fluctuations and is considered to be riskier than ARQT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	ADMA	ARQT	Difference
Volatility (1M) Calculated over the trailing 1-month period	32.15%	15.32%	+16.83%
Volatility (6M) Calculated over the trailing 6-month period	44.57%	43.81%	+0.76%
Volatility (1Y) Calculated over the trailing 1-year period	57.46%	60.16%	-2.70%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	59.98%	71.95%	-11.97%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	69.11%	77.53%	-8.42%

Financials

ADMA vs. ARQT - Profitability Comparison

The chart below illustrates the profitability comparison between ADMA Biologics, Inc. and Arcutis Biotherapeutics, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

ADMA - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, ADMA Biologics, Inc. reported a gross profit of 88.82M and revenue of 139.16M. Therefore, the gross margin over that period was 63.8%.

ARQT - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Arcutis Biotherapeutics, Inc. reported a gross profit of 117.82M and revenue of 129.50M. Therefore, the gross margin over that period was 91.0%.

ADMA - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, ADMA Biologics, Inc. reported an operating income of 62.75M and revenue of 139.16M, resulting in an operating margin of 45.1%.

ARQT - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Arcutis Biotherapeutics, Inc. reported an operating income of 18.39M and revenue of 129.50M, resulting in an operating margin of 14.2%.

ADMA - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, ADMA Biologics, Inc. reported a net income of 49.38M and revenue of 139.16M, resulting in a net margin of 35.5%.

ARQT - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Arcutis Biotherapeutics, Inc. reported a net income of 17.40M and revenue of 129.50M, resulting in a net margin of 13.4%.